|
Originally published In Press as doi:10.1074/jbc.M106981200 on August 29, 2001
J. Biol. Chem., Vol. 276, Issue 46, 43145-43151, November 16, 2001
Design and Characterization of a Highly Selective Peptide
Inhibitor of the Small Conductance Calcium-activated K+
Channel, SkCa2*
Vikram G.
Shakkottai §¶,
Imed
Regaya§ ,
Heike
Wulff ,
Ziad
Fajloun ,
Hiroaki
Tomita ,
Mohamed
Fathallah **,
Michael D.
Cahalan ,
J. Jay
Gargus ,
Jean-Marc
Sabatier , and
K. George
Chandy
From the Department of Physiology and Biophysics,
University of California, Irvine, California 92697, CNRS Unité Mixte de Recherche 6560, Faculté de
Médecine Nord 13014, Marseille, France, and ** CIC
9502, Assistance Publique des Hôpitaux de Marseille-INSERM,
Hôpital Sainte Marguerite, Marseille 13009, France
Received for publication, July 24, 2001, and in revised form, August 29, 2001
 |
ABSTRACT |
Apamin-sensitive small conductance
calcium-activated potassium channels (SKCa1-3) mediate the slow
afterhyperpolarization in neurons, but the molecular identity of the
channel has not been defined because of the lack of specific
inhibitors. Here we describe the structure-based design of a selective
inhibitor of SKCa2. Leiurotoxin I (Lei) and PO5, peptide toxins
that share the RXCQ motif, potently blocked human
SKCa2 and SKCa3 but not SKCa1, whereas maurotoxin, Pi1, Ts , and PO1
were ineffective. Lei blocked these channels more potently than PO5
because of the presence of Ala1, Phe2, and
Met7. By replacing Met7 in the RXCQ
motif of Lei with the shorter, unnatural, positively charged
diaminobutanoic acid (Dab), we generated Lei-Dab7, a
selective SKCa2 inhibitor (Kd = 3.8 nM)
that interacts with residues in the external vestibule of the channel.
SKCa3 was rendered sensitive to Lei-Dab7 by replacing
His521 with the corresponding SKCa2 residue
(Asn367). Intracerebroventricular injection of
Lei-Dab7 into mice resulted in no gross central nervous
system toxicity at concentrations that specifically blocked SKCa2
homotetramers. Lei-Dab7 will be a useful tool to
investigate the functional role of SKCa2 in mammalian tissues.
 |
INTRODUCTION |
Ca2+-activated K+
(KCa)1 channels
modulate cytosolic Ca2+ concentrations in excitable and
non-excitable tissues by regulating the membrane potential. Based on
their unitary conductance, KCa channels are classified
as BKCa, IKCa, and
SKCa (1). Opening in response to an increase in
cytosolic [Ca2+]i in the 200-500
nM range (2), SKCa channels modulate the
firing pattern of neurons by generating slow membrane after hyperpolarizations (3-5). In the liver, they are believed to play a
role in metabolic stress responses (6), and in human Jurkat T cells,
they promote calcium entry in response to a mitogenic stimulus (7).
SKCa channels have also been implicated in
fasciculations in denervated skeletal muscle (8) and in myotonic
dystrophy (9). SKCa channels, products of three
phylogenetically related genes SKCa1-3, are found in a
variety of tissues including the nervous system (10), liver (11),
skeletal and smooth muscle (8, 12), adrenal medulla (13), and lymphoid
tissues (14, 15). In the brain (16), the precise functional role of
each channel in specific neuronal pathways has been difficult to
elucidate because of the absence of selective blockers. The identity of the specific SKCa channel(s) responsible for
apamin-induced destruction of cerebellar Purkinje neurons (17) and
altered seizure threshold (18, 19) and for apamin and Lei neurotoxicity
(20) is also unclear. The development of inhibitors that target each of
these channels selectively would facilitate studies to determine their specific roles in mammalian tissues.
The SKCa2 channel is expressed in the brain (10,
16), retina (21), liver (22), melanocytes (expressed sequence tag AA418096), fetal heart (expressed sequence tag AA418000), and human
Jurkat T cell line (7, 22, 23). Precise determination of function has
only been possible in Jurkat T lymphocytes in which this channel plays
a role in calcium signaling (7, 14, 24). The existing blockers of SKCa2
channels are not adequately specific to distinguish this channel from
other SKCa subtypes. Apamin, a peptide from bee venom,
exhibits only 10-fold selectivity for human SKCa2 over human SKCa1 or
SKCa3 (3, 22, 25, 26), while the bisquinolinium cyclophane
UCL-1684 blocks SKCa2 and SKCa1 with roughly equivalent potency
(25) although it shows some selectivity over SKCa3 (7). The peptide
toxin Lei (also known as scyllatoxin) from the scorpion Leiurus
quinquestriatus hebraeus, currently the most specific inhibitor of
SKCa2, exhibits ~200-fold selectivity for human SKCa2 (15) over SKCa1
(25), although its affinity for SKCa3 had not been determined.
This study describes the guided design and electrophysiological
characterization of a novel Lei analog that selectively blocks SKCa2
homotetramers with low nanomolar affinity. Our strategy to design a
specific inhibitor of the SKCa2 channel exploited an approach used
previously to develop selective blockers of Kv1.3 and IKCa1 channels
(27, 28). In this approach, a potent yet non-selective inhibitor of the
target channel is the starting template. Specificity for the desired
channel is engineered into the peptide on the basis of experimentally
determined differences in its interaction with the target channel and
other channels. Using Lei and a closely related peptide PO5 as
templates, and by comparing the potencies of the native and mutant
toxins for SKCa1, SKCa2, and SKCa3, we delineated the channel-binding
surfaces of these toxins. Lei-Dab7 was designed to target a
structural feature unique to the Lei-SKCa2 interaction surface.
 |
EXPERIMENTAL PROCEDURES |
Peptide Synthesis--
N- -Fmoc-L-amino
acid derivatives, Fmoc-amide resin, and chemical reagents used for
peptide synthesis were purchased from PerkinElmer Life Sciences
(Shelton, CO), Novabiochem (Laufelfingen, Switzerland), and Neosystem
Laboratoire (Strasbourg, France). Solvents were analytical grade
products from SDS (Peypin, France). The various peptides were
synthesized by the stepwise solid-phase method (29) using a peptide
synthesizer (Model 433A, Applied Biosystems Inc., Foster City, CA). The
side-chain protecting groups used for trifunctional residues were:
2,2,5,7,8-pentamethylchromane-6-sulfonyl for Arg and
homoarginine; tert-butyloxycarbonyl for Orn, Lys, and
homolysine, and
1-(4,4-dimethyl-2,6-dioxocyclohex-1-yliden)-3-methylbutyl for Dab and
diaminopropionic acid (Dapa). The reduced peptides were dissolved at 1 mM in 0.2 M Tris-HCl buffer, pH 8.3, and
stirred under air to allow folding/oxidation (48 h, 25 °C). The
folded/oxidized toxins and their structural analogs were purified to
homogeneity by reversed-phase high-pressure liquid chromatography
(HPLC) (PerkinElmer Life Sciences), C18 Aquapore ODS 20 µm, 250 × 10 mm). The homogeneity (>99%) and identity of the
peptides were verified by: (i) analytical C18
reversed-phase HPLC, (ii) amino acid content determination after
acidolysis, and (iii) mass analysis by matrix-assisted laser desorption
ionization-time of flight mass spectrometry.
Cell Culture--
Jurkat E6-1, COS-7, and PC12 cells were
obtained from ATCC (Manassas, VA). Jurkat E6-1 cells were grown in
RPMI medium supplemented with 10% fetal bovine serum, 2 mM
glutamine, and 10 mM HEPES at densities of 1-9 × 105 in a 37 °C humidified incubator with 5%
CO2. COS-7 and PC12 cells were cultured in Dulbecco's
modified Eagle's medium containing 10% fetal calf serum and 2 mM glutamine and split twice weekly. Unless otherwise
specified, all reagents were obtained from Sigma.
Clones and Mutants--
The cloning of human SKCa3
containing 19 polyglutamines in the N terminus
(GenBankTM AF031815, AJ251016) and IKCa1
(GenBankTM AF033021) has been reported previously (30-32).
The full coding region of SKCa1 was amplified from human
brain total RNA using reverse transcriptase polymerase chain reaction
(PCR) with an engineered 5' HindIII site near the start
codon and a 3' BamHI site near the termination codon and was
cloned in-frame into the pEGFP-C3 vector
(CLONTECH, Palo Alto, CA) to create
GFP-SKCa1. PCR was used to generate mutant SKCa3 channels
(28). PCR products were digested with KpnI and
BamHI and cloned into KpnI and
BamHI-cut GFP-SKCa3. All clones were
verified by sequencing. DNA for transfection was prepared with the
QIAGEN (Valencia, CA) Miniprep kit. Human SKCa2 in
pcDNA3 was a generous gift from Dr. Bernard Attali (Tel Aviv
University, Sackler School of Medicine, Israel).
Transfection of Constructs into Mammalian Cells--
COS-7 cells
were plated in culture chambers (5 × 105
cells/chamber), and 12-24 h later, cells were transiently transfected using FuGeneTM 6 (Roche Molecular Biochemicals) with the
respective DNA in serum-free OptiMEM medium (Life Technologies, Inc.)
as per the manufacturer's recommended protocol. GFP-positive cells
were used for electrophysiological studies at 48 h following
transfection. Typical transfection efficiencies using this protocol
were 40-70%. PC12 cells were plated overnight on glass coverslips
prior to use. Cell lines stably expressing mKv1.1, mKv1.3, and hKv1.5,
hSlo, and RBL cells expressing endogenous rKir 2.1 were used for the
selectivity screen as described previously (28).
Electrophysiology--
Cells were studied in the whole cell
configuration of the patch clamp technique. The holding potential in
all experiments was 80 mV. For measurement of IKCa,
SKCa, and BKCa currents, we used an
internal pipette solution containing (in mM) 145 potassium aspartate, 2 MgCl2, 10 HEPES, 10 K2EGTA, and 8.5 CaCl2 (1 µM free Ca2+), pH 7.2, 290-310 mOsm. KV currents were
recorded with a fluoride-based internal solution. To reduce currents
from native chloride channels in COS-7, sodium aspartate Ringer was
used as an external solution (in mM) 160 sodium aspartate,
4.5 KCl, 2 CaCl2, 1 MgCl2, and 5 HEPES, pH 7.4, 290-310 mOsm. For Jurkat T cells, potassium aspartate Ringer was used
as an external solution with K+ instead of Na+
(164.5 mM K+). SKCa currents
were elicited by 200-ms voltage ramps from 120 to 40 mV applied every
10 s, and the reduction of slope conductance at 80 mV by the
toxin was taken as a measure of channel block. BKCa
currents were elicited by 200-ms voltage ramps from 80 to 80 mV
applied every 30 s, and channel block measured at 35 mV. The
inward rectifier (rKir 2.1) in RBL cells was studied in sodium aspartate Ringer with a potassium aspartate-based pipette solution containing 50 nM free Ca2+.
Selective in Vivo Blockade of SKCa2 Channels by
Lei-Dab7 in Mice--
Lei-Dab7 was
administered to 25-g C57/BL6 mice via the
intracerebroventricular route, and the LD50 was
determined (33). Groups of four mice per dose were injected with 5 µl
of the peptide solution containing 0.1% (w/v) bovine serum albumin and
0.9% (w/v) sodium chloride.
 |
RESULTS |
Lei and PO5 Are Potent Inhibitors of Human SKCa
Channels--
Six peptide toxins from scorpion venom have been
identified as SKCa channel blockers based on
125I-apamin displacement studies on rat brain synaptosomes
(34). Fig. 1 shows the sequence alignment
of these toxins (35), three of which (Lei, PO5, and Pi1) contain a
motif (RXCQ) reported to be important for binding to
SKCa channels. (20, 36). Apamin contains an RRCQ
sequence (Fig. 1), which has a spatial arrangement similar to that of
the RMCQ motif in Lei (Fig. 2).

View larger version (30K):
[in this window]
[in a new window]
|
Fig. 1.
Sequence alignment of known
SKCa blockers showing subfamilies
4, 5, 6, and 8 from scorpion venom (28) and apamin. The conserved
RXCQ motif is boxed. The differing residues of
Lei and PO5 are highlighted. MTX,
maurotoxin.
|
|

View larger version (19K):
[in this window]
[in a new window]
|
Fig. 2.
Superimposition of the backbone structures of
Lei (yellow) and apamin (blue).
The RXCQ motif is boxed. Inset,
RXCQ motif in both toxins on a larger scale.
|
|
Lei is reported to block the well characterized human SKCa2 channel in
Jurkat T cells with picomolar potency (15, 22, 23). As the first step
in our strategy to design a specific SKCa2 inhibitor, we compared the
potency of Lei with that of PO5, a toxin that differs from Lei only at
positions 1, 2, 7, and 24 (Fig. 1), in blocking Jurkat SKCa2. Symmetric
internal and external K+ solutions were used to induce the
inward component of the SKCa2 current. Following break-in with 1 µM Ca2+ in the pipette solution, SKCa2
currents were seen at negative potentials. At potentials more positive
than 40 mV, K+ currents were mainly due to Kv1.3 with
minimal contribution from SKCa2 (Fig.
3A, left). The
SKCa2 component was blocked by Lei and PO5, whereas the Kv1.3 current
was unaffected (Fig. 3A, left). Dose-response
curves showed that Lei blocked Jurkat SKCa2 with Kd
values consistent with published data on the cloned and native
channel (15, 22, 23) and with ~100-fold greater potency than PO5
(Fig. 3B and Table I).
Lei and PO5 were next evaluated on cloned SKCa1 and SKCa3 expressed in
COS-7 cells. SKCa1 (Fig. 3A, middle) and SKCa3
(Fig. 3A, right) K+ currents elicited
with 1 µM Ca2+ in the pipette solution
reversed at 80 mV in the presence of external sodium Ringer. Lei and
PO5 blocked SKCa3 but were ineffective on SKCa1 (Fig. 3A and
Table I). Comparison of the dose-response curves of SKCa3 showed Lei to
be 25-fold more effective than PO5 (Fig. 3B and Table I).
For reasons that remain unclear, four other scorpion toxins
(maurotoxin, Pi1, PO1, and Ts ) reported to be highly active in
125I-apamin displacement assays (20, 34, 36) had little or no blocking activity on SKCa2 or SKCa3 (Table I). Thus, the two most
potent scorpion peptides, Lei and PO5, exhibited significantly different blocking potencies on SKCa2 and SKCa3 despite differing at
only four positions.

View larger version (24K):
[in this window]
[in a new window]
|
Fig. 3.
Effect of Lei and PO5 on SKCa1-3.
A, typical current traces on the three
SK channels showing block with Lei
and PO5. SKCa2 and Kv1.3 (left); SKCa1 (middle);
SKCa3 (right). B, dose-response curves
of Lei and PO5 on SKCa1-3. Lei on hSKCa1 ( , straight
line, Kd = 325 nM); Lei on hSKCa2
( , straight line, Kd = 0.2 nM); Lei on hSKCa3 ( , straight line,
Kd = 1.1 nM); PO5 on hSKCa2 ( ,
dashed line, Kd = 22.1 nM);
and PO5 on hSKCa3 ( , dashed line, Kd = 25.1 nM). Only one concentration of PO5 was tested on SKCa1
(shown). Typical SKCa1-3 currents were studied in the whole cell
configuration of the patch clamp technique. Recordings were done with 1 µM free calcium as the internal pipette solution, and
currents were elicited by voltage ramps from 120 to 40 mV. SKCa1 and
SKCa3 were expressed transiently in COS-7 cells. An external solution
containing sodium aspartate (5 mM potassium aspartate) was
used for the recordings, and the degree of block was measured as the
decrease in slope conductance at 80 mV. Jurkat T-cells were used to
assess the effect on endogenous hSKCa2 with symmetric internal and
external potassium aspartate (165 mM potassium
aspartate).
|
|
View this table:
[in this window]
[in a new window]
|
Table I
Comparison of competition data on rat brain synaptosomes of indicated
toxins (20, 34, 36) with Kd values by patch clamp on hSKCa2
and hSKCa3
|
|
Ala1, Phe2, and Met7 in Lei Are
Responsible for the Enhanced Potency of Lei over PO5--
To define
the residues responsible for the increased affinity of Lei for
SKCa channels, we replaced each of the four differing residues in PO5 with the corresponding residue in Lei. PO5-V24D blocked
SKCa2 and SKCa3 with a potency comparable with native PO5 (Fig.
4A). PO5-T1A, PO5-V2F, and
PO5-R7M blocked SKCa2 with potencies approaching that of Lei. The
improved potency of all three PO5 mutants to nearly that of Lei
suggests that any of the indicated alterations in the side chains at
these positions may allow PO5 to fit more tightly within the
channel-binding pocket due to either shorter side-chain size or local
change in backbone conformation (37, 38). Similar results were obtained
with these PO5 mutants on SKCa3 (Fig. 4B). The reverse
mutation in Lei (Lei-M7R) reduced potency on both SKCa2 and SKCa3 (data
not shown). These results indicate that Ala1,
Phe2, and Met7 underlie the increased affinity
of Lei over PO5 for SKCa2 and SKCa3. These three residues form a
localized binding pocket that may represent an important contact point
with SKCa channels (Fig. 5, A and B).

View larger version (14K):
[in this window]
[in a new window]
|
Fig. 4.
Histograms showing the effect of replacement
of Thr1, Val2, Arg7, and
Val24 in PO5 with the corresponding residues in Lei in
blocking SKCa2 (A) and SKCa3
(B). The Kd values of native
toxin is shown for comparison.
|
|

View larger version (69K):
[in this window]
[in a new window]
|
Fig. 5.
Space-filling models of Lei
(left) and PO5 (right) showing
residues at positions 1, 2, 7, and 24 (A) and the
conserved RXCQ motif (B).
X = methionine in Lei and arginine in PO5.
|
|
Lei-Dab7 Is a Highly Selective Inhibitor of
SKCa2--
Positions 6 and 7 of Lei are part of the conserved
RXCQ motif (Fig. 1). To define the role of the residues in
this motif, a series of Lei mutants was made at positions 6 and 7 to
probe the toxin-channel interaction. Charge-neutralization mutations at
position 6 that retained size (Arg6 leucine or
citrulline) reduced toxin potency 70-180-fold for both channels (Fig.
6), indicating the need for a charged
residue at this position. Substitution of the unbranched lysine at
position 6, a mutation that retained charge but decreased size, also
reduced toxin affinity for both channels (20-35-fold), whereas the
introduction of the positively charged, bulky branched unnatural amino
acid, homoarginine, caused a 1000-fold decrease in toxin potency (Fig. 6). Thus, substitutions at position 6 are not tolerated, and the arginine has the optimum size, charge, and branching required for
interaction with SKCa channels. Furthermore, when
residues at positions 6 and 7 were exchanged, the Lei-R6M+M7R double
mutant was considerably less potent than the native toxin on SKCa2 and SKCa3 (Kd = 9.5 and 65 nM,
respectively), establishing the importance of the relative locations of
Arg6 and Met7 in the RXCQ motif.

View larger version (23K):
[in this window]
[in a new window]
|
Fig. 6.
Effect of substitutions at position 6 of Lei
in blocking SKCa2 (left) and SKCa3
(right). The respective Kd
values is shown on the right. Numbers in
parentheses indicate the number of times tested.
|
|
We next turned our attention to position 7 in the
RXCQ motif and found our first promising lead. Introduction
of positively charged lysine at position 7 (Lei-M7K) yielded a mutant
that blocked SKCa2 35-fold more potently than SKCa3 (Fig.
7). In an attempt to further enhance this
difference, we generated two additional Lei mutants in which
Met7 was replaced by smaller positively charged unnatural
amino acids diaminopropionate (Lei-Dapa7) and
diaminobutanoate (Lei-Dab7). Lei-Dapa7 blocked
Jurkat SKCa2 ~350-fold more potently than SKCa3, whereas Lei-Dab7 was ~650-fold more effective. Similar results
were obtained with the cloned SKCa2 channel expressed in COS-7 cells
(Table II). Lei-Dab7 was also
ineffective against hSKCa1, hIKCa1, hSlo, KV, and Kir channels, establishing its specificity for SKCa2 (Table II).

View larger version (26K):
[in this window]
[in a new window]
|
Fig. 7.
Effect of substitutions at position 7 of Lei
in blocking SKCa2 (left) and SKCa3
(right). The respective Kd
values is shown on the right. Numbers in
parentheses indicate the number of times tested.
|
|
Asn367 in the SKCa2 Pore Region Is Important for
Lei-Dab7 Selectivity--
Because Lei-Dab7 and
apamin share the critical RXCQ channel-binding motif (Figs.
1 and 2), it is likely that Lei-Dab7, like apamin (39),
binds to residues in the external S5-Pore-S6 region of the
channel. Human SKCa2 and SKCa3 differ at only two positions in the pore
region (Fig. 8A). To determine
whether one or both these residues contribute to Lei-Dab7
selectivity (Fig. 8, B and C), we replaced these
two residues in SKCa3 (Val485 and His521) with
the corresponding residues of SKCa2 (Ala331 and
Asn367), individually or together. Lei-Dab7
blocked SKCa3-H521N (Kd = 20 ± 4.7 nM) and SKCa3-V485A + H521N (Kd = 7.5 ± 1.2 nM) with nearly the same potency as SKCa2
(Fig. 8, D and E, and Table II), whereas
SKCa3-V485A did not produce functional channels. In mutant cycle
studies with the SKCa3-H521N and SKCa3-V485A+H521N mutants, residue 7 of Lei-Dab7 was found to couple tightly with
His521 ( G = 2.4), suggesting that these two
residues lie in close proximity to each other. We conclude that
Lei-Dab7 binds to the external vestibule of
SKCa channels and that Asn367 (the residue
corresponding to His521 of hSKCa3) in SKCa2 contributes to
Lei-Dab7 selectivity.

View larger version (28K):
[in this window]
[in a new window]
|
Fig. 8.
Effect of replacement of differing residues
in the S5-Pore-S6 region in SKCa3 with the corresponding residues in
SKCa2. A, sequence alignment of SKCa2 and SKCa3 S5-Pore-S6
region with the two differing residues underlined.
B, 10 nM Lei-Dab7 on native SKCa2
(Kd = 3.8 nM ± 0.5 nM).
C, 1000 nM Lei-Dab7 on hSKCa3
(Kd = 2500 ± 500 nM).
D, 100 nM Lei-Dab7 on hSKCa3-H521N
(Kd = 20 ± 4.7 nM). E,
10 nM Lei-Dab7 on hSKCa3-V485A+H521N
(Kd = 7.5 nM ± 1.2 nM).
|
|
Selective in Vivo Blockade of Homotetrameric SKCa2 Channels
by Lei-Dab7 Does Not Cause Gross Neurotoxicity--
To
evaluate the central nervous system effects of specific in
vivo blockade of SKCa2 homotetramers, Lei-Dab7 was
administered via the intracerebroventricular route to mice. At a
concentration (10 ng (or 300 nM assuming a brain liquid
volume of 10 µl)) that would selectively block >99% of SKCa2
homotetramers, no gross central nervous system toxicity was observed.
At a higher concentration (50 ng (or 1500 nM)), all six
animals became hyperexcitable, developed convulsions followed by
paralysis lasting 15 h, and then fully recovered. At much higher
concentrations (80 ng (or 2400 nM)), 50% of the animals
died within 2 h, and 100% lethality was observed in 1 h at
100 ng (3 µM). The neurotoxicity observed at
Lei-Dab7 concentrations higher than 1500 nM may
be due to the blockade of SKCa1 and/or SKCa3 homotetrameric channels
(Table II), although we cannot exclude the contribution of
heteromultimeric SKCa channels containing SKCa2 subunits.
 |
DISCUSSION |
Functional SKCa channels are
tetramers of SKCa1-3 subunits that can assemble as homo- or
heterooligomers (39). Heterooligomers are likely to exist natively
given the overlapping patterns of distribution of SKCa1-3 in the
central nervous system. SKCa1 and SKCa2 are abundant in the
hippocampus, whereas the medial habenula has both SKCa2 and SKCa3 (10,
16). The available SKCa channel inhibitors, including
apamin (3, 22, 25, 26) and the UCL compounds (7, 25), do not have the
requisite selectivity to define the specific functional roles of the
homo- and heterooligomeric SKCa channels present in
mammalian tissues. In this study, we used a structure-guided approach
to develop Lei-Dab7, a novel peptide that blocks SKCa2
homotetramers with nanomolar potency and exhibits 650-fold or greater
selectivity over related homooligomeric channels. Heterooligomeric
SKCa channels may exhibit intermediate sensitivity for
Lei-Dab7 compared with their homotetrameric counterparts as
has been shown with apamin on recombinant heterotetramers of SKCa1 and
SKCa2 (39).
Lei-Dab7 might help elucidate the contributions
of SKCa2 channels in mediating neuronal afterhyperpolarization (3-5)
and in the apamin-induced destruction of cerebellar Purkinje neurons (17) and altered seizure threshold (18, 19). Lei-Dab7 may
also help define the role of SKCa2 in the retina, liver, melanocytes,
immune system, and fetal heart. The subunit composition of
SKCa heterooligomers in diverse mammalian tissues may
also be determined by using Lei-Dab7 in much the same way
as radiolabeled peptide toxins selective for a particular
KV subunit have proven useful in assessing the subunit
composition of brain heteromeric KV channels (40-42).
Peptide inhibitors of SKCa channels form a
structurally distinct group and lack the conserved dyad present in
peptide blockers of KV, IKCa1, and BKCa
channels that consists of an aromatic residue with a neighboring
invariant lysine (43). Therefore, the architecture of the toxin-binding
surface in the external vestibule of SKCa channels may
differ from that of KV (44-47) and IKCa1 (28, 48) channels, which are similar to that of the crystallographically defined
structure of the bacterial K+ channel, KcsA (49,
50). The topologies of KV and IKCa1 channels were deduced
from toxin mapping studies by identifying multiple contact points
between toxins of known structure and these channels. Lei-Dab7 may similarly be used as a molecular caliper to
delineate the architecture of the external vestibule of SKCa2 . Molecular models of SKCa channels based on
complementary mutagenesis studies would facilitate the development of
selective and potent inhibitors of SKCa1 and SKCa3.
 |
ACKNOWLEDGEMENTS |
We thank Chialing Wu and Dr.
Luette Forrest for technical assistance, Dr. Pascal Mansuelle for amino
acid analyses and Edman sequencing, and Prof. Herve Rochat for constant support.
 |
FOOTNOTES |
*
This study was supported by Grant MH59222 from the National
Institutes of Health (to K. G. C.), by an American Heart
Association Fellowship (to H. W.), and by CNRS and Cellpep S.A.
(Paris, France) funds.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
§
These two authors contributed equally to this work and should be
considered co-first authors.
¶
To whom correspondence should be addressed: Rm. 291, Joan
Irvine Smith Hall, Medical School, University of California, Irvine, CA
92697. Tel.: 949-824-2133; Fax: 949-824-3143; E-mail:
vshakkot@uci.edu.
Published, JBC Papers in Press, August 29, 2001, DOI 10.1074/jbc.M106981200
 |
ABBREVIATIONS |
The abbreviations used are:
KCa, calcium-activated K+ channel;
SKCa, small conductance KCa;
BKCa, large conductance KCa;
IKCa, intermediate conductance KCa;
Lei, leiurotoxin I;
Dab, diaminobutanoic acid;
Dapa, diaminopropionic acid;
GFP, green fluorescent protein;
Fmoc, N-(9-fluorenyl)methoxycarbonyl;
HPLC, high-pressure liquid
chromatography.
 |
REFERENCES |
| 1.
|
Latorre, R.,
Oberhauser, A.,
Labarca, P.,
and Alvarez, O.
(1989)
Annu. Rev. Physiol.
51,
385-399[CrossRef][Medline]
[Order article via Infotrieve]
|
| 2.
|
Hirschberg, B.,
Maylie, J.,
Adelman, J. P.,
and Marrion, N. V.
(1998)
J. Gen. Physiol.
111,
565-581[Abstract/Free Full Text]
|
| 3.
|
Kohler, M.,
Hirschberg, B.,
Bond, C. T.,
Kinzie, J. M.,
Marrion, N. V.,
Maylie, J.,
and Adelman, J. P.
(1996)
Science
273,
1709-1714[Abstract/Free Full Text]
|
| 4.
|
Sah, P.
(1996)
Trends Neurosci.
19,
150-154[CrossRef][Medline]
[Order article via Infotrieve]
|
| 5.
|
Xia, X. M.,
Fakler, B.,
Rivard, A.,
Wayman, G.,
Johnson-Pais, T.,
Keen, J. E.,
Ishii, T.,
Hirschberg, B.,
Bond, C. T.,
Lutsenko, S.,
Maylie, J.,
and Adelman, J. P.
(1998)
Nature
395,
503-507[CrossRef][Medline]
[Order article via Infotrieve]
|
| 6.
|
Barfod, E. T.,
Moore, A. L.,
and Lidofsky, S. D.
(2001)
Am. J. Physiol.
280,
C836-C842[Abstract/Free Full Text]
|
| 7.
|
Fanger, C. M.,
Rauer, H.,
Neben, A. L.,
Miller, M. J.,
Rauer, H.,
Wulff, H.,
Rosa, J. C.,
Ganellin, C. R.,
Chandy, K. G.,
and Cahalan, M. D.
(2001)
J. Biol. Chem.
276,
12249-12256[Abstract/Free Full Text]
|
| 8.
|
Pribnow, D.,
Johnson-Pais, T.,
Bond, C. T.,
Keen, J.,
Johnson, R. A.,
Janowsky, A.,
Silvia, C.,
Thayer, M.,
Maylie, J.,
and Adelman, J. P.
(1999)
Muscle Nerve
22,
742-750[CrossRef][Medline]
[Order article via Infotrieve]
|
| 9.
|
Kimura, T.,
Takahashi, M. P.,
Okuda, Y.,
Kaido, M.,
Fujimura, H.,
Yanagihara, T.,
and Sakoda, S.
(2000)
Neurosci. Lett.
295,
93-96[CrossRef][Medline]
[Order article via Infotrieve]
|
| 10.
|
Rimini, R.,
Rimland, J. M.,
and Terstappen, G. C.
(2000)
Brain Res.
85,
218-220[CrossRef]
|
| 11.
|
Jenkinson, D. H.,
Haylett, D. G.,
and Cook, N. S.
(1983)
Cell Calcium
4,
429-437[CrossRef][Medline]
[Order article via Infotrieve]
|
| 12.
|
Paolocci, N.,
Pagliaro, P.,
Isoda, T.,
Saavedra, F. W.,
and Kass, D. A.
(2001)
Circulation
103,
119-124[Abstract/Free Full Text]
|
| 13.
|
Nagayama, T.,
Fukushima, Y.,
Hikichi, H.,
Yoshida, M.,
Suzuki-Kusaba, M.,
Hisa, H.,
Kimura, T.,
and Satoh, S.
(2000)
Am. J. Physiol.
279,
R1731-R1736[Abstract/Free Full Text]
|
| 14.
|
Grissmer, S.,
Lewis, R. S.,
and Cahalan, M. D.
(1992)
J. Gen. Physiol.
99,
63-84[Abstract/Free Full Text]
|
| 15.
|
Hanselmann, C.,
and Grissmer, S.
(1996)
J. Physiol. (Lond.)
496,
627-637[Abstract/Free Full Text]
|
| 16.
|
Stocker, M.,
and Pedarzani, P.
(2000)
Mol. Cell. Neurosci.
15,
476-493[CrossRef][Medline]
[Order article via Infotrieve]
|
| 17.
|
Mourre, C.,
Fournier, C.,
and Soumireu-Mourat, B.
(1997)
Brain Res.
778,
405-408[CrossRef][Medline]
[Order article via Infotrieve]
|
| 18.
|
McCown, T. J.,
and Breese, G. R.
(1990)
Eur. J. Pharmacol.
187,
49-58[CrossRef][Medline]
[Order article via Infotrieve]
|
| 19.
|
Empson, R.,
and Jefferys, J.
(2001)
Neuroscience
102,
297-306[CrossRef][Medline]
[Order article via Infotrieve]
|
| 20.
|
Sabatier, J. M.,
Fremont, V.,
Mabrouk, K.,
Crest, M.,
Darbon, H.,
Rochat, H.,
Van Rietschoten, J.,
and Martin-Eauclaire, M. F.
(1994)
Int. J. Pept. Protein Res.
43,
486-495[Medline]
[Order article via Infotrieve]
|
| 21.
|
Klocker, N.,
Oliver, D.,
Ruppersberg, J.,
Knaus, H.,
and Fakler, B.
(2001)
Mol. Cell. Neurosci.
17,
514-520[CrossRef][Medline]
[Order article via Infotrieve]
|
| 22.
|
Desai, R.,
Peretz, A.,
Idelson, H.,
Lazarovici, P.,
and Attali, B.
(2000)
J. Biol. Chem.
275,
39954-39963[Abstract/Free Full Text]
|
| 23.
|
Jaeger, H.,
Adelman, J. P.,
and Grissmer, S.
(2000)
FEBS Lett.
469,
196-202[CrossRef][Medline]
[Order article via Infotrieve]
|
| 24.
|
Grissmer, S.,
Nguyen, A. N.,
and Cahalan, M. D.
(1993)
J. Gen. Physiol.
102,
601-630[Abstract/Free Full Text]
|
| 25.
|
Stroebaek, D.,
Joergensen, T. D.,
Christophersen, P.,
Ahring, P. K.,
and Olesen, S. P.
(2000)
Br. J. Pharmacol.
129,
991-999[CrossRef][Medline]
[Order article via Infotrieve]
|
| 26.
|
Shah, M.,
and Haylett, D. G.
(2000)
Br. J. Pharmacol.
129,
627-630[CrossRef][Medline]
[Order article via Infotrieve]
|
| 27.
|
Kalman, K.,
Pennington, M. W.,
Lanigan, M. D.,
Nguyen, A.,
Rauer, H.,
Mahnir, V.,
Paschetto, K.,
Kem, W. R.,
Grissmer, S.,
Gutman, G. A.,
Christian, E. P.,
Cahalan, M. D.,
Norton, R. S.,
and Chandy, K. G.
(1998)
J. Biol. Chem.
273,
32697-32707[Abstract/Free Full Text]
|
| 28.
|
Rauer, H.,
Lanigan, M. D.,
Pennington, M. W.,
Aiyar, J.,
Ghanshani, S.,
Cahalan, M. D.,
Norton, R. S.,
and Chandy, K. G.
(2000)
J. Biol. Chem.
275,
1201-1208[Abstract/Free Full Text]
|
| 29.
|
Merrifield, B.
(1986)
Science
232,
341-347[Free Full Text]
|
| 30.
|
Chandy, K. G.,
Fantino, E.,
Wittekindt, O.,
Kalman, K.,
Tong, L. L.,
Ho, T. H.,
Gutman, G. A.,
Crocq, M. A.,
Ganguli, R.,
Nimgaonkar, V.,
Morris- Rosendahl, D. J.,
and Gargus, J. J.
(1998)
Mol. Psychiatry
3,
32-37[CrossRef][Medline]
[Order article via Infotrieve]
|
| 31.
|
Logsdon, N. J.,
Kang, J.,
Togo, J. A.,
Christian, E. P.,
and Aiyar, J.
(1997)
J. Biol. Chem.
272,
32723-32726[Abstract/Free Full Text]
|
| 32.
|
Ghanshani, S.,
Coleman, M.,
Gustavsson, P.,
Wu, A. C.,
Gargus, J. J.,
Gutman, G. A.,
Dahl, N.,
Mohrenweiser, H.,
and Chandy, K. G.
(1998)
Genomics
51,
160-161[CrossRef][Medline]
[Order article via Infotrieve]
|
| 33.
|
Behrens, B.,
and Karber, C.
(1935)
Arch. Exp. Pathol. Pharmakol.
177,
379-388
|
| 34.
|
Fajloun, Z.,
Carlier, E.,
Lecomte, C.,
Geib, S.,
Di Luccio, E.,
Bichet, D.,
Mabrouk, K.,
Rochat, H.,
De Waard, M.,
and Sabatier, J. M.
(2000)
Eur. J. Biochem.
267,
5149-5155[Medline]
[Order article via Infotrieve]
|
| 35.
|
Tytgat, J.,
Chandy, K.,
Garcia, M.,
Gutman, G.,
Martin-Eauclaire, M.,
van der Walt, J.,
and Possani, L.
(2000)
Trends Pharmacol. Sci.
20,
444-447
|
| 36.
|
Sabatier, J. M.,
Zerrouk, H.,
Darbon, H.,
Mabrouk, K.,
Benslimane, A.,
Rochat, H.,
Martin-Eauclaire, M. F.,
and Van Rietschoten, J.
(1993)
Biochemistry
32,
2763-2770[CrossRef][Medline]
[Order article via Infotrieve]
|
| 37.
|
Rajamohan, F.,
Alzate, O.,
Cotrill, J. A.,
Curtiss, A.,
and Dean, D. H.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
14338-14343[Abstract/Free Full Text]
|
| 38.
|
Smith, L. A.,
Reid, P. F.,
Wang, F. C.,
Parcej, D. N.,
Schmidt, J. J.,
Olson, M. A.,
and Dolly, J. O.
(1997)
Biochemistry
36,
7690-7696[CrossRef][Medline]
[Order article via Infotrieve]
|
| 39.
|
Ishii, T. M.,
Maylie, J.,
and Adelman, J. P.
(1997)
J. Biol. Chem.
272,
23195-23200[Abstract/Free Full Text]
|
| 40.
|
Scott, V. E.,
Muniz, Z. M.,
Sewing, S.,
Lichtinghagen, R.,
Parcej, D. N.,
Pongs, O.,
and Dolly, J. O.
(1994)
Biochemistry
33,
1617-1623[CrossRef][Medline]
[Order article via Infotrieve]
|
| 41.
|
Koschak, A.,
Bugianesi, R. M.,
Mitterdorfer, J.,
Kaczorowski, G. J.,
Garcia, M. L.,
and Knaus, H. G.
(1998)
J. Biol. Chem.
273,
2639-2644[Abstract/Free Full Text]
|
| 42.
|
Koch, R. O.,
Wanner, S. G.,
Koschak, A.,
Hanner, M.,
Schwarzer, C.,
Kaczorowski, G. J.,
Slaughter, R. S.,
Garcia, M. L.,
and Knaus, H. G.
(1997)
J. Biol. Chem.
272,
27577-27581[Abstract/Free Full Text]
|
| 43.
|
Dauplais, M.,
Lecoq, A.,
Song, J.,
Cotton, J.,
Jamin, N.,
Gilquin, B.,
Roumestand, C.,
Vita, C.,
de Medeiros, C. L. C.,
Rowan, E. G.,
Harvey, A. L.,
and Menez, A.
(1997)
J. Biol. Chem.
272,
4302-4309[Abstract/Free Full Text]
|
| 44.
|
Aiyar, J.,
Withka, J. M.,
Rizzi, J. P.,
Singleton, D. H.,
Andrews, G. C.,
Lin, W.,
Boyd, J.,
Hanson, D. C.,
Simon, M.,
Dethlefs, B.,
Lee, C.-L.,
Hall, J. E.,
Gutman, G. A.,
and Chandy, K. G.
(1995)
Neuron
15,
1169-1181[CrossRef][Medline]
[Order article via Infotrieve]
|
| 45.
|
Aiyar, J.,
Rizzi, J. P.,
Gutman, G. A.,
and Chandy, K. G.
(1996)
J. Biol. Chem.
271,
31013-31016[Abstract/Free Full Text]
|
| 46.
|
Hidalgo, P.,
and MacKinnon, R.
(1995)
Science
268,
307-310[Abstract/Free Full Text]
|
| 47.
|
Ranganathan, R.,
Lewis, J. H.,
and MacKinnon, R.
(1996)
Neuron
16,
131-139[CrossRef][Medline]
[Order article via Infotrieve]
|
| 48.
|
Rauer, H.,
Pennington, M.,
Cahalan, M.,
and Chandy, K. G.
(1999)
J. Biol. Chem.
274,
21885-21892[Abstract/Free Full Text]
|
| 49.
|
Doyle, D. A.,
Morais Cabral, J.,
Pfuetzner, R. A.,
Kuo, A.,
Gulbis, J. M.,
Cohen, S. L.,
Chait, B. T.,
and MacKinnon, R.
(1998)
Science
280,
69-77[Abstract/Free Full Text]
|
| 50.
|
MacKinnon, R.,
Cohen, S. L.,
Kuo, A.,
Lee, A.,
and Chait, B. T.
(1998)
Science
280,
106-109[Abstract/Free Full Text]
|
Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
A. Nolting, T. Ferraro, D. D'hoedt, and M. Stocker
An Amino Acid Outside the Pore Region Influences Apamin Sensitivity in Small Conductance Ca2+-activated K+ Channels
J. Biol. Chem.,
February 9, 2007;
282(6):
3478 - 3486.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Potier, V. Joulin, S. Roger, P. Besson, M.-L. Jourdan, J.-Y. LeGuennec, P. Bougnoux, and C. Vandier
Identification of SK3 channel as a new mediator of breast cancer cell migration.
Mol. Cancer Ther.,
November 1, 2006;
5(11):
2946 - 2953.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Strobaek, C. Hougaard, T. H. Johansen, U. S. Sorensen, E. O. Nielsen, K. S. Nielsen, R. D. T. Taylor, P. Pedarzani, and P. Christophersen
Inhibitory Gating Modulation of Small Conductance Ca2+-Activated K+ Channels by the Synthetic Compound (R)-N-(Benzimidazol-2-yl)-1,2,3,4-tetrahydro-1-naphtylamine (NS8593) Reduces Afterhyperpolarizing Current in Hippocampal CA1 Neurons
Mol. Pharmacol.,
November 1, 2006;
70(5):
1771 - 1782.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C.-Q. Xu, B. Brone, D. Wicher, O. Bozkurt, W.-Y. Lu, I. Huys, Y.-H. Han, J. Tytgat, E. Van Kerkhove, and C.-W. Chi
BmBKTx1, a Novel Ca2+-activated K+ Channel Blocker Purified from the Asian Scorpion Buthus martensi Karsch
J. Biol. Chem.,
August 13, 2004;
279(33):
34562 - 34569.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Sultan, M. Gosling, S. Abu-Hayyeh, N. Carey, and J. T. Powell
Flow-dependent increase of ICAM-1 on saphenous vein endothelium is sensitive to apamin
Am J Physiol Heart Circ Physiol,
July 1, 2004;
287(1):
H22 - H28.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. A. Kramar, B. Lin, C.-Y. Lin, A. C. Arai, C. M. Gall, and G. Lynch
A Novel Mechanism for the Facilitation of Theta-Induced Long-Term Potentiation by Brain-Derived Neurotrophic Factor
J. Neurosci.,
June 2, 2004;
24(22):
5151 - 5161.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. D'hoedt, K. Hirzel, P. Pedarzani, and M. Stocker
Domain Analysis of the Calcium-activated Potassium Channel SK1 from Rat Brain: FUNCTIONAL EXPRESSION AND TOXIN SENSITIVITY
J. Biol. Chem.,
March 26, 2004;
279(13):
12088 - 12092.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
O. H. Wittekindt, V. Visan, H. Tomita, F. Imtiaz, J. J. Gargus, F. Lehmann-Horn, S. Grissmer, and D. J. Morris-Rosendahl
An Apamin- and Scyllatoxin-Insensitive Isoform of the Human SK3 Channel
Mol. Pharmacol.,
March 1, 2004;
65(3):
788 - 801.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. A. Castle, D. O. London, C. Creech, Z. Fajloun, J. W. Stocker, and J.-M. Sabatier
Maurotoxin: A Potent Inhibitor of Intermediate Conductance Ca2+-Activated Potassium Channels
Mol. Pharmacol.,
February 1, 2003;
63(2):
409 - 418.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Pedarzani, D. D'hoedt, K. B. Doorty, J. D. F. Wadsworth, J. S. Joseph, K. Jeyaseelan, R. M. Kini, S. V. Gadre, S. M. Sapatnekar, M. Stocker, et al.
Tamapin, a Venom Peptide from the Indian Red Scorpion (Mesobuthus tamulus) That Targets Small Conductance Ca2+-activated K+ Channels and Afterhyperpolarization Currents in Central Neurons
J. Biol. Chem.,
November 22, 2002;
277(48):
46101 - 46109.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2001 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|